Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer

BACKGROUND Previous studies have evaluated 3‐week and weekly docetaxel schedules in patients with metastatic breast cancer (MBC). The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and more efficacious....

Ausführliche Beschreibung